Back to search

Article

Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)

2024-09-11

Abstract excerpt

Despite the approval of PD-(L)1 inhibitors for the first-line treatment of all metastatic, driver-negative, non-small cell lung cancer patients (mNSCLC) in the United States since 2018, there still is a lack discerning biomarkers to predict which patients will derive significant benefit. Tumor expression of programmed-death ligand 1 (PD-L1), measured as the tumor proportion score (TPS), is a standard biomarker app...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d89b3993-3b73-5044-bd0c-87e67360c44d
DOI
10.1101/2024.09.09.24313374
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)DOI 10.1101/2024.09.09.24313374
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.Semantic proximity
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsSemantic proximity
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Semantic proximity
PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?Semantic proximity
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity
Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity
Select a neighboring publication to make it the new centre.